首页 > 最新文献

Neoplasma最新文献

英文 中文
Tumor-targeted suicide gene-directed enzyme prodrug therapy mediated by extracellular vesicles. 细胞外囊泡介导的肿瘤靶向自杀基因导向酶前药治疗。
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230328N172
Jana Jakubechova, Ursula Altanerova, Cestmir Altaner

In this article, we describe the gene-directed enzyme prodrug therapy, also known as the "Trojan Horse" therapy mediated by exosomes - small extracellular vesicles (sEVs) secreted from mesenchymal stem/stromal cells (MSCs) and cancer cells. MSC-EVs possess strong migrating tropism toward tumor sites. EVs derived from tumor cells mimic the parental cells in an invasive metastatic growth trait and the capability to reprogram the recipient cells. The behavior of these EVs when modified with the suicide gene predestinates them to be a drug with guided intracellular action. EVs with therapeutic suicide gene are prepared from cells with integrated retrovirus vector containing its genetic message. These EVs are internalized by tumor cells and the product of the gene converts the non-toxic prodrug into a cytotoxic drug inside the cell causing its suicide. The action of two suicide gene systems are described: the yCD::UPRT-MSC/5-FC system and the HSVTK-MSC-GCV system. Suicide gene EVs either MSCs or tumor cell origin due to their intrinsic targeting capabilities, high modification flexibility, as well as biological barrier permeability represent potential drugs for tumors untreatable with present standard cancer therapies.

在这篇文章中,我们描述了基因导向的酶前药物治疗,也被称为“特洛伊木马”治疗,由外泌体介导-从间充质干细胞/基质细胞(MSCs)和癌细胞分泌的小细胞外囊泡(sev)。msc - ev对肿瘤部位具有强烈的迁移倾向。来源于肿瘤细胞的ev在侵袭性转移性生长特性和对受体细胞重编程的能力上模仿亲本细胞。当这些ev被自杀基因修饰后,它们的行为决定了它们是一种具有引导细胞内作用的药物。以细胞为载体,利用整合的逆转录病毒载体制备治疗性自杀基因ev。这些ev被肿瘤细胞内化,基因的产物将无毒的前药转化为细胞毒性药物,导致细胞自杀。描述了两种自杀基因系统的作用:yCD::UPRT-MSC/5-FC系统和HSVTK-MSC-GCV系统。自杀基因EVs,无论是MSCs还是肿瘤细胞起源,由于其固有的靶向能力、高修饰灵活性以及生物屏障渗透性,代表了目前标准癌症治疗无法治疗的肿瘤的潜在药物。
{"title":"Tumor-targeted suicide gene-directed enzyme prodrug therapy mediated by extracellular vesicles.","authors":"Jana Jakubechova,&nbsp;Ursula Altanerova,&nbsp;Cestmir Altaner","doi":"10.4149/neo_2023_230328N172","DOIUrl":"https://doi.org/10.4149/neo_2023_230328N172","url":null,"abstract":"<p><p>In this article, we describe the gene-directed enzyme prodrug therapy, also known as the \"Trojan Horse\" therapy mediated by exosomes - small extracellular vesicles (sEVs) secreted from mesenchymal stem/stromal cells (MSCs) and cancer cells. MSC-EVs possess strong migrating tropism toward tumor sites. EVs derived from tumor cells mimic the parental cells in an invasive metastatic growth trait and the capability to reprogram the recipient cells. The behavior of these EVs when modified with the suicide gene predestinates them to be a drug with guided intracellular action. EVs with therapeutic suicide gene are prepared from cells with integrated retrovirus vector containing its genetic message. These EVs are internalized by tumor cells and the product of the gene converts the non-toxic prodrug into a cytotoxic drug inside the cell causing its suicide. The action of two suicide gene systems are described: the yCD::UPRT-MSC/5-FC system and the HSVTK-MSC-GCV system. Suicide gene EVs either MSCs or tumor cell origin due to their intrinsic targeting capabilities, high modification flexibility, as well as biological barrier permeability represent potential drugs for tumors untreatable with present standard cancer therapies.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"333-339"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma. 边缘可切除和局部晚期胰腺腺癌的化疗与化疗放疗。
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230409N193
Soňa Argalácsová, Michal Vočka, Luboš Petruželka, Miroslav Ryska, Pavel Záruba, Zdeněk Krška, Vladimír Frýba, Jan Ulrych, Vladimír Černý, Tomáš Tůma, David Hoskovec

The role of radiotherapy in borderline resectable (BRPC) and locally advanced pancreatic carcinoma (LAPC) remains controversial. In our study, we retrospectively evaluated 48 patients with BRPC (14; 29.2%) and LAPC (34; 70. 8%) who underwent 6-8 cycles of induction mFOLFIRINOX chemotherapy alone (23; 47.9%) or 4-6 cycles of mFOLFIRINOX followed by hypofractionated radiotherapy (up to the total dose of 39.9 Gy in 15 fractions) (25; 52.1%). Survival parameters were evaluated using the Gehan-Breslow-Wilcoxon Test and compared by using the long-rank test. The addition of radiotherapy was not associated with better survival (16.9 months for chemotherapy only versus 15.9 months for the combined therapy; p=0.486), as well as for both subgroups (13.5 months vs. 18.3 months; p=0.679) and (20.7 months vs. 13.8 months; p=0.425) for BRPC and LAPC, respectively. A higher resection rate was seen in the BRPC group compared to the LAPC group (43% vs. 17.6%, respectively). Our study revealed a significantly higher rate of lung metastases in patients after the combination therapy compared to those treated by chemotherapy only (19% vs. 0%, respectively; p=0.045). Such a borderline result, however, prevents us from drawing clear conclusions about whether this is an artifact caused by the low number of patients or whether radiotherapy leads to a selection of stem cells with a predilection to the generalization to the lungs.

放疗在边界可切除(BRPC)和局部晚期胰腺癌(LAPC)中的作用仍存在争议。在我们的研究中,我们对 48 例 BRPC(14 例,占 29.2%)和 LAPC(34 例,占 70.8%)患者进行了回顾性评估,这些患者接受了 6-8 个周期的 mFOLFIRINOX 诱导化疗(23 例,占 47.9%)或 4-6 个周期的 mFOLFIRINOX 诱导化疗后的低分次放疗(总剂量达 39.9 Gy,分 15 次进行)(25 例,占 52.1%)。采用Gehan-Breslow-Wilcoxon检验评估生存参数,并采用长秩检验进行比较。在BRPC和LAPC两个亚组中,加用放疗与更高的生存率无关(仅化疗为16.9个月,联合治疗为15.9个月;P=0.486),也与更高的生存率无关(分别为13.5个月vs.18.3个月;P=0.679)和(20.7个月vs.13.8个月;P=0.425)。与 LAPC 组相比,BRPC 组的切除率更高(分别为 43% 对 17.6%)。我们的研究显示,与仅接受化疗的患者相比,接受联合疗法的患者肺转移率明显更高(分别为 19% 对 0%;P=0.045)。然而,这种边缘性结果使我们无法得出明确的结论,即这是由于患者人数较少而造成的假象,还是放疗导致干细胞的选择偏向于转移到肺部。
{"title":"Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma.","authors":"Soňa Argalácsová, Michal Vočka, Luboš Petruželka, Miroslav Ryska, Pavel Záruba, Zdeněk Krška, Vladimír Frýba, Jan Ulrych, Vladimír Černý, Tomáš Tůma, David Hoskovec","doi":"10.4149/neo_2023_230409N193","DOIUrl":"10.4149/neo_2023_230409N193","url":null,"abstract":"<p><p>The role of radiotherapy in borderline resectable (BRPC) and locally advanced pancreatic carcinoma (LAPC) remains controversial. In our study, we retrospectively evaluated 48 patients with BRPC (14; 29.2%) and LAPC (34; 70. 8%) who underwent 6-8 cycles of induction mFOLFIRINOX chemotherapy alone (23; 47.9%) or 4-6 cycles of mFOLFIRINOX followed by hypofractionated radiotherapy (up to the total dose of 39.9 Gy in 15 fractions) (25; 52.1%). Survival parameters were evaluated using the Gehan-Breslow-Wilcoxon Test and compared by using the long-rank test. The addition of radiotherapy was not associated with better survival (16.9 months for chemotherapy only versus 15.9 months for the combined therapy; p=0.486), as well as for both subgroups (13.5 months vs. 18.3 months; p=0.679) and (20.7 months vs. 13.8 months; p=0.425) for BRPC and LAPC, respectively. A higher resection rate was seen in the BRPC group compared to the LAPC group (43% vs. 17.6%, respectively). Our study revealed a significantly higher rate of lung metastases in patients after the combination therapy compared to those treated by chemotherapy only (19% vs. 0%, respectively; p=0.045). Such a borderline result, however, prevents us from drawing clear conclusions about whether this is an artifact caused by the low number of patients or whether radiotherapy leads to a selection of stem cells with a predilection to the generalization to the lungs.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"468-475"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Function, drug resistance and prognostic effect of AKR1C2 in human cancer. AKR1C2在人类肿瘤中的功能、耐药及预后作用。
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230206N66
Zhao Wang, Yue Feng, Jiayu Song, Di Sun, Yun-Yan Zhang
Aldo-keto reductases (ARKs), a group of reductases that rely on nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) to catalyze carbonyl, are widely found in various organisms, which play an important role in the physiological and pathological processes of human. Aldo-keto reductase family 1 member C2 (AKR1C2) as a member of the human ARKs family, can regulate steroid hormones and is abnormally expressed in many cancers. According to whether the tumor can be affected by hormones, we divide malignancies into hormone-dependent and hormone-independent types. Studies have shown that AKR1C2 is involved in regulating tumor invasion, migration, and other malignant phenotypes, eliminating reactive oxygen species (ROS), promoting chemotherapy resistance of tumor cells, and has prognostic value in some cancers. Here, we focus on the role and clinical significance of AKR1C2 in different types of tumors.
醛酮还原酶(ARKs)是一类依赖于烟酰胺腺嘌呤二核苷酸(NADH)和烟酰胺腺嘌呤二核苷酸磷酸(NADPH)催化羰基的还原酶,广泛存在于各种生物体中,在人体的生理和病理过程中起着重要作用。Aldo-keto还原酶家族1成员C2 (AKR1C2)作为人类ARKs家族的一员,可以调节类固醇激素,在许多癌症中异常表达。根据肿瘤是否受激素影响,我们将恶性肿瘤分为激素依赖型和激素独立型。研究表明,AKR1C2参与调节肿瘤侵袭、迁移等恶性表型,消除活性氧(reactive oxygen species, ROS),促进肿瘤细胞化疗耐药,在某些癌症中具有预后价值。本文主要探讨AKR1C2在不同类型肿瘤中的作用及临床意义。
{"title":"Function, drug resistance and prognostic effect of AKR1C2 in human cancer.","authors":"Zhao Wang,&nbsp;Yue Feng,&nbsp;Jiayu Song,&nbsp;Di Sun,&nbsp;Yun-Yan Zhang","doi":"10.4149/neo_2023_230206N66","DOIUrl":"https://doi.org/10.4149/neo_2023_230206N66","url":null,"abstract":"Aldo-keto reductases (ARKs), a group of reductases that rely on nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH) to catalyze carbonyl, are widely found in various organisms, which play an important role in the physiological and pathological processes of human. Aldo-keto reductase family 1 member C2 (AKR1C2) as a member of the human ARKs family, can regulate steroid hormones and is abnormally expressed in many cancers. According to whether the tumor can be affected by hormones, we divide malignancies into hormone-dependent and hormone-independent types. Studies have shown that AKR1C2 is involved in regulating tumor invasion, migration, and other malignant phenotypes, eliminating reactive oxygen species (ROS), promoting chemotherapy resistance of tumor cells, and has prognostic value in some cancers. Here, we focus on the role and clinical significance of AKR1C2 in different types of tumors.","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"319-332"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9890418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA SLC7A11-AS1 promotes the progression of hepatocellular carcinoma by mediating KLF9 ubiquitination. LncRNA SLC7A11-AS1通过介导KLF9泛素化促进肝癌的进展。
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230323N162
Fan-Lin Zeng, Jie Lin, Xing Xie, Yuan-Kang Xie, Jian-Hong Zhang, Daofeng Xu, Xiao He, Feng En Liu, Bin-Hui Xie

Hepatocellular carcinoma (HCC) is a malignant tumor, which seriously threatens the life of patients. LncRNA SLC7A11-AS1 was reported to be abnormally expressed in HCC. Here, the functions and relative molecular regulatory mechanism of SLC7A11-AS1 in HCC were investigated. Nude mice and HCC cells were used as the experimental subjects. Knockdown or overexpression of exogenous genes was conducted in HCC cells. RT-qPCR, IHC, and western blot were employed to evaluate the abundance of genes and proteins. The malignant behaviors were evaluated using CCK-8, clone formation, wound-healing, and Transwell. The locations of SLC7A11-AS1 and KLF9 in cells were determined by FISH and IF assays. The total m6A level was evaluated by dot-blot assay. m6A modification of SLC7A11-AS1 was detected using RNA MeRIP. The interactions among molecules were validated by RIP, ChIP, dual luciferase reporter assay, and co-IP. SLC7A11-AS1 was elevated apparently in HCC cells and HCC tissues from mice. SLC7A11-AS1 silencing could suppress HCC progression, which was validated in in vivo and in vitro experiments. Furthermore, METTL3 mediated m6A modification of SLC7A11-AS1 to elevate its expression. In addition, SLC7A11-AS1 downregulated KLF9 expression by affecting STUB1-mediated ubiquitination degradation and KLF9 enhanced PHLPP2 expression to inactivate the AKT pathway. Eventually, rescue experiments revealed that KLF9 knockdown abolished SLC7A11-AS1 silencing-mediated suppression of HCC progression in vivo and in vitro. Our results unveiled that m6A-modified SLC7A11-AS1 promoted HCC progression by regulating the STUB1/KLF9/PHLPP2/AKT axis, indicating that targeting SLC7A11-AS1 might alleviate HCC progression.

肝细胞癌(HCC)是一种严重威胁患者生命的恶性肿瘤。LncRNA SLC7A11-AS1被报道在HCC中异常表达。本文探讨SLC7A11-AS1在HCC中的功能及相关分子调控机制。以裸鼠和肝癌细胞为实验对象。在HCC细胞中进行外源基因的敲低或过表达。RT-qPCR、免疫组化和western blot检测基因和蛋白的丰度。采用CCK-8、克隆形成、创面愈合、Transwell等方法评价恶性行为。SLC7A11-AS1和KLF9在细胞中的位置通过FISH和IF测定。用点印迹法测定总m6A水平。采用RNA MeRIP检测SLC7A11-AS1的m6A修饰。通过RIP、ChIP、双荧光素酶报告基因实验和co-IP验证分子间的相互作用。SLC7A11-AS1在小鼠肝癌细胞和肝癌组织中明显升高。SLC7A11-AS1沉默可以抑制HCC的进展,这在体内和体外实验中得到了验证。此外,METTL3介导m6A修饰SLC7A11-AS1以提高其表达。此外,SLC7A11-AS1通过影响stub1介导的泛素化降解下调KLF9表达,KLF9通过增强PHLPP2表达使AKT通路失活。最终,救援实验显示,KLF9敲除可在体内和体外消除SLC7A11-AS1沉默介导的肝癌进展抑制。我们的研究结果显示,m6a修饰的SLC7A11-AS1通过调节STUB1/KLF9/PHLPP2/AKT轴促进HCC进展,表明靶向SLC7A11-AS1可能缓解HCC进展。
{"title":"LncRNA SLC7A11-AS1 promotes the progression of hepatocellular carcinoma by mediating KLF9 ubiquitination.","authors":"Fan-Lin Zeng,&nbsp;Jie Lin,&nbsp;Xing Xie,&nbsp;Yuan-Kang Xie,&nbsp;Jian-Hong Zhang,&nbsp;Daofeng Xu,&nbsp;Xiao He,&nbsp;Feng En Liu,&nbsp;Bin-Hui Xie","doi":"10.4149/neo_2023_230323N162","DOIUrl":"https://doi.org/10.4149/neo_2023_230323N162","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a malignant tumor, which seriously threatens the life of patients. LncRNA SLC7A11-AS1 was reported to be abnormally expressed in HCC. Here, the functions and relative molecular regulatory mechanism of SLC7A11-AS1 in HCC were investigated. Nude mice and HCC cells were used as the experimental subjects. Knockdown or overexpression of exogenous genes was conducted in HCC cells. RT-qPCR, IHC, and western blot were employed to evaluate the abundance of genes and proteins. The malignant behaviors were evaluated using CCK-8, clone formation, wound-healing, and Transwell. The locations of SLC7A11-AS1 and KLF9 in cells were determined by FISH and IF assays. The total m6A level was evaluated by dot-blot assay. m6A modification of SLC7A11-AS1 was detected using RNA MeRIP. The interactions among molecules were validated by RIP, ChIP, dual luciferase reporter assay, and co-IP. SLC7A11-AS1 was elevated apparently in HCC cells and HCC tissues from mice. SLC7A11-AS1 silencing could suppress HCC progression, which was validated in in vivo and in vitro experiments. Furthermore, METTL3 mediated m6A modification of SLC7A11-AS1 to elevate its expression. In addition, SLC7A11-AS1 downregulated KLF9 expression by affecting STUB1-mediated ubiquitination degradation and KLF9 enhanced PHLPP2 expression to inactivate the AKT pathway. Eventually, rescue experiments revealed that KLF9 knockdown abolished SLC7A11-AS1 silencing-mediated suppression of HCC progression in vivo and in vitro. Our results unveiled that m6A-modified SLC7A11-AS1 promoted HCC progression by regulating the STUB1/KLF9/PHLPP2/AKT axis, indicating that targeting SLC7A11-AS1 might alleviate HCC progression.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"361-374"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9890421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Circular RNA_0000326 accelerates breast cancer development via modulation of the miR-9-3p/YAP1 axis. 环状RNA_0000326通过调节miR-9-3p/YAP1轴加速乳腺癌的发展。
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_220904N894
Xiao-Ling Xue, Shuai Zhao, Meng-Chang Xu, Ying Li, Wen-Fei Liu, Hong-Zhen Qin

Circular RNA (circ)_0000326 has been reported in bladder cancer and cervical cancer and is concerned to be involved with the development of cancerous cells. Whereas, there have been no reports concentrating on the influences of circ_0000326 in breast cancer (BC). Therefore, the latent modulatory mechanisms of circ_0000326 in BC are researched. circ_0000326 expression in BC tissues and correlative cells was evaluated via RT-qPCR, and the relevance between circ_0000326 expression and overall survival and the clinicopathological feature was also investigated. After a series of transfection, the effects of circ_0000326, microRNA-9-3p (miR-9-3p), and Yes-associated protein 1 (YAP1) in BC cell growth, invasion, and stemness were studied by CCK-8, flow cytometry, Transwell, and sphere-forming assays. The binding sites and correlation of circ_0000326, miR-9-3p, and YAP1 were certified via starBase website, luciferase reporter assay, and Pearson's χ2 test. The in vivo experiment was evaluated by establishing a subcutaneous tumorigenesis model. High-expressed circ_0000326 in BC tissues and cells was discovered, which was connected with an undesirable prognosis. Silencing of circ_0000326 visibly inhibited MCF-7 and BT549 cell growth, invasion, stemness, meanwhile declining the protein levels of SRY-related high-mobility group box gene 2 (SOX2) and octamer binding transcription factor 4 (OCT4). miR-9-3p was a sponger of circ_0000326, which was negatively regulated by circ_0000326. Moreover, YAP1 was confirmed as a target gene of miR-9-3p. circ_0000326 affected BC cell behaviors via mediating miR-9-3p and YAP1. Furthermore, circ_0000326 silencing prohibited tumor growth of BC in vivo. The research uncovered that circ_0000326 facilitated BC development via mediating the miR-9-3p/YAP1 axis.

环状RNA (circ)_0000326已被报道在膀胱癌和宫颈癌中发现,并被认为与癌细胞的发展有关。然而,目前还没有关于circ_0000326对乳腺癌(BC)影响的报道。因此,本文对circ_0000326在BC中的潜在调节机制进行了研究。RT-qPCR检测circ_0000326在BC组织及相关细胞中的表达,并探讨circ_0000326表达与总生存率及临床病理特征的相关性。经过一系列转染后,通过CCK-8、流式细胞术、Transwell和球形成实验研究circ_0000326、microRNA-9-3p (miR-9-3p)和Yes-associated protein 1 (YAP1)对BC细胞生长、侵袭和干细胞性的影响。circ_0000326、miR-9-3p和YAP1的结合位点和相关性通过starBase网站、荧光素酶报告基因法、Pearson χ2检验进行鉴定。通过建立皮下肿瘤发生模型对体内实验进行评价。circ_0000326在BC组织和细胞中高表达,与预后不良有关。沉默circ_0000326可明显抑制MCF-7和BT549细胞的生长、侵袭和干性,同时降低sry相关高迁移率群盒基因2 (SOX2)和八聚体结合转录因子4 (OCT4)的蛋白水平。miR-9-3p是circ_0000326的海绵,circ_0000326负向调控miR-9-3p。此外,YAP1被证实是miR-9-3p的靶基因。circ_0000326通过介导miR-9-3p和YAP1影响BC细胞行为。此外,circ_0000326沉默可在体内抑制BC的肿瘤生长。研究发现circ_0000326通过介导miR-9-3p/YAP1轴促进BC的发展。
{"title":"Circular RNA_0000326 accelerates breast cancer development via modulation of the miR-9-3p/YAP1 axis.","authors":"Xiao-Ling Xue,&nbsp;Shuai Zhao,&nbsp;Meng-Chang Xu,&nbsp;Ying Li,&nbsp;Wen-Fei Liu,&nbsp;Hong-Zhen Qin","doi":"10.4149/neo_2023_220904N894","DOIUrl":"https://doi.org/10.4149/neo_2023_220904N894","url":null,"abstract":"<p><p>Circular RNA (circ)_0000326 has been reported in bladder cancer and cervical cancer and is concerned to be involved with the development of cancerous cells. Whereas, there have been no reports concentrating on the influences of circ_0000326 in breast cancer (BC). Therefore, the latent modulatory mechanisms of circ_0000326 in BC are researched. circ_0000326 expression in BC tissues and correlative cells was evaluated via RT-qPCR, and the relevance between circ_0000326 expression and overall survival and the clinicopathological feature was also investigated. After a series of transfection, the effects of circ_0000326, microRNA-9-3p (miR-9-3p), and Yes-associated protein 1 (YAP1) in BC cell growth, invasion, and stemness were studied by CCK-8, flow cytometry, Transwell, and sphere-forming assays. The binding sites and correlation of circ_0000326, miR-9-3p, and YAP1 were certified via starBase website, luciferase reporter assay, and Pearson's χ2 test. The in vivo experiment was evaluated by establishing a subcutaneous tumorigenesis model. High-expressed circ_0000326 in BC tissues and cells was discovered, which was connected with an undesirable prognosis. Silencing of circ_0000326 visibly inhibited MCF-7 and BT549 cell growth, invasion, stemness, meanwhile declining the protein levels of SRY-related high-mobility group box gene 2 (SOX2) and octamer binding transcription factor 4 (OCT4). miR-9-3p was a sponger of circ_0000326, which was negatively regulated by circ_0000326. Moreover, YAP1 was confirmed as a target gene of miR-9-3p. circ_0000326 affected BC cell behaviors via mediating miR-9-3p and YAP1. Furthermore, circ_0000326 silencing prohibited tumor growth of BC in vivo. The research uncovered that circ_0000326 facilitated BC development via mediating the miR-9-3p/YAP1 axis.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"430-442"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9921465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new pathway for the transformation of AML in MDS: APA mechanism regulated by NUDT21 and RUNX1. AML在MDS中的转化新途径:由NUDT21和RUNX1调控的APA机制
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230115N27
Shuo Li, Fanggang Ren, Xiao-Li Liu, Hong-Yu Zhang, Zhi-Fang Xu, Daniel Muteb Muyey, Zhuanzhen Zheng, Yan-Hong Tan, Xiu-Hua Chen, Hong-Wei Wang

We have identified that NUDT21 plays a vital role in MDS transformations, while the transcription factor RUNX1 is essential for normal hematopoiesis, which is a high expression in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and we aim to explore the linkage between the two genes and new pathways for MDS transformation to AML. Prediction of RUNX1 expression levels and its relationship with NUDT21 in AML and MDS patients was performed using bioinformatics techniques and validated in patients. Using lentiviral packaging technology, NUDT21 knockdown and overexpression models were developed in AML and MDS cell lines. These models were validated using quantitative polymerase chain reaction (qPCR) and western blotting. The cell cycle, apoptosis, differentiation, and cytokines were examined by flow cytometry, CCK-8 analyzed proliferation, and the intracellular localization of NUDT21 and RUNX1 was examined by immunofluorescence. mRNA transcriptome sequencing was performed on THP-1, MUTZ-1, and Dapars analyzed SKM-1 cell lines and the sequencing data to observe the knockdown effect of NUDT21 on RUNX1. qPCR and western blot revealed a positive correlation between NUDT21 and RUNX1; both were located in the nucleus. Overexpression of NUDT21 reduced apoptosis, promoted cell proliferation, and possibly increased the invasive ability of cells. It also altered the APA site in the RUNX1 3'-UTRs region. NUDT21 regulates RUNX1 gene expression and promotes AML transformation in MDS through an APA mechanism.

我们已经发现NUDT21在MDS转化中起着至关重要的作用,而转录因子RUNX1对于正常造血至关重要,在急性髓性白血病(AML)和骨髓增生异常综合征(MDS)中高表达,我们的目标是探索这两个基因之间的联系以及MDS转化为AML的新途径。利用生物信息学技术预测AML和MDS患者RUNX1表达水平及其与NUDT21的关系,并在患者中进行验证。利用慢病毒包装技术,在AML和MDS细胞系中建立了NUDT21敲低和过表达模型。使用定量聚合酶链反应(qPCR)和western blotting对这些模型进行验证。流式细胞术检测细胞周期、凋亡、分化和细胞因子,CCK-8分析细胞增殖,免疫荧光检测NUDT21和RUNX1的细胞内定位。对THP-1、MUTZ-1进行mRNA转录组测序,Dapars分析SKM-1细胞系及测序数据,观察NUDT21对RUNX1的敲低作用。qPCR和western blot结果显示NUDT21与RUNX1呈正相关;两者都位于细胞核中。过表达NUDT21可减少细胞凋亡,促进细胞增殖,并可能增加细胞的侵袭能力。它还改变了RUNX1 3'-UTRs区域的APA位点。NUDT21通过APA机制调控RUNX1基因表达,促进MDS的AML转化。
{"title":"A new pathway for the transformation of AML in MDS: APA mechanism regulated by NUDT21 and RUNX1.","authors":"Shuo Li,&nbsp;Fanggang Ren,&nbsp;Xiao-Li Liu,&nbsp;Hong-Yu Zhang,&nbsp;Zhi-Fang Xu,&nbsp;Daniel Muteb Muyey,&nbsp;Zhuanzhen Zheng,&nbsp;Yan-Hong Tan,&nbsp;Xiu-Hua Chen,&nbsp;Hong-Wei Wang","doi":"10.4149/neo_2023_230115N27","DOIUrl":"https://doi.org/10.4149/neo_2023_230115N27","url":null,"abstract":"<p><p>We have identified that NUDT21 plays a vital role in MDS transformations, while the transcription factor RUNX1 is essential for normal hematopoiesis, which is a high expression in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and we aim to explore the linkage between the two genes and new pathways for MDS transformation to AML. Prediction of RUNX1 expression levels and its relationship with NUDT21 in AML and MDS patients was performed using bioinformatics techniques and validated in patients. Using lentiviral packaging technology, NUDT21 knockdown and overexpression models were developed in AML and MDS cell lines. These models were validated using quantitative polymerase chain reaction (qPCR) and western blotting. The cell cycle, apoptosis, differentiation, and cytokines were examined by flow cytometry, CCK-8 analyzed proliferation, and the intracellular localization of NUDT21 and RUNX1 was examined by immunofluorescence. mRNA transcriptome sequencing was performed on THP-1, MUTZ-1, and Dapars analyzed SKM-1 cell lines and the sequencing data to observe the knockdown effect of NUDT21 on RUNX1. qPCR and western blot revealed a positive correlation between NUDT21 and RUNX1; both were located in the nucleus. Overexpression of NUDT21 reduced apoptosis, promoted cell proliferation, and possibly increased the invasive ability of cells. It also altered the APA site in the RUNX1 3'-UTRs region. NUDT21 regulates RUNX1 gene expression and promotes AML transformation in MDS through an APA mechanism.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"350-360"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9925126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study. 多西紫杉醇治疗新发转移性激素敏感前列腺癌预后的预测因素:一项单中心队列研究
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_221220N1190
Tomislav Omrčen, Davor Eterović, Tea Jozić, Eduard Vrdoljak

Six cycles of docetaxel in addition to androgen deprivation therapy (ADT) are currently one of the treatment options for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Since the outcomes in patients with high-volume (HV) disease remain modest, we aimed to identify patients for more intensified treatment. We report a cohort of 73 consecutive patients with de novo mHSPC treated with early docetaxel at the Department of Oncology and Radiotherapy, University Hospital of Split, Croatia, from October 2015 until March 2020. The outcomes analyzed were the occurrence of castration-resistant disease (CRPC) and death from any cause (OS). The median follow-up was 54 (50-73) months. Forty-six (63%) patients developed CRPC and 34 (47%) died during the follow-up. The median time to CRPC and median OS were 16.2 and 58.4 months, respectively. The risk of CRPC was higher for patients with high (above median) values of serum alkaline phosphatase (ALP) (HR=2.4; 95% CI [1.4-4.5]), lactate dehydrogenase (LDH) (HR=1.98; 95% CI [1.1-3.7]), prostate-specific antigen (PSA) (HR=1.8; 95% CI [1.1-3]), ECOG performance status >1 (HR=2; 95% CI [1.2-3.3]) and HV disease (HR=1.9; 95% CI [1.1-3.1]). The risk of any-cause death was higher in patients with high values of ALP, LDH, and ECOG performance status >1. The predictive value of LDH was independent of disease volume. A set of baseline characteristics could be used in conjunction with disease volume in deciding on the optimal treatment strategy for patients with de novo mHSPC.

6个周期的多西紫杉醇加雄激素剥夺治疗(ADT)是目前新发转移性激素敏感前列腺癌(mHSPC)患者的治疗选择之一。由于高容量(HV)疾病患者的预后仍然温和,我们的目标是确定需要更强化治疗的患者。我们报告了2015年10月至2020年3月在克罗地亚斯普利特大学医院肿瘤和放疗科接受早期多西紫杉醇治疗的73例连续新生mHSPC患者队列。结果分析为去势抵抗性疾病(CRPC)的发生和任何原因死亡(OS)。中位随访时间为54(50-73)个月。46例(63%)患者发生CRPC, 34例(47%)患者在随访期间死亡。到CRPC和OS的中位时间分别为16.2个月和58.4个月。血清碱性磷酸酶(ALP)值高(高于中位数)的患者发生CRPC的风险更高(HR=2.4;95% CI[1.4-4.5]),乳酸脱氢酶(LDH) (HR=1.98;95% CI[1.1-3.7])、前列腺特异性抗原(PSA) (HR=1.8;95% CI [1.1-3]), ECOG性能状态>1 (HR=2;95% CI[1.2-3.3])和HV疾病(HR=1.9;95% ci[1.1-3.1])。ALP、LDH和ECOG表现>1的患者发生任何原因死亡的风险更高。LDH的预测价值与疾病体积无关。一组基线特征可与疾病量一起用于决定新发mHSPC患者的最佳治疗策略。
{"title":"Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study.","authors":"Tomislav Omrčen,&nbsp;Davor Eterović,&nbsp;Tea Jozić,&nbsp;Eduard Vrdoljak","doi":"10.4149/neo_2023_221220N1190","DOIUrl":"https://doi.org/10.4149/neo_2023_221220N1190","url":null,"abstract":"<p><p>Six cycles of docetaxel in addition to androgen deprivation therapy (ADT) are currently one of the treatment options for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Since the outcomes in patients with high-volume (HV) disease remain modest, we aimed to identify patients for more intensified treatment. We report a cohort of 73 consecutive patients with de novo mHSPC treated with early docetaxel at the Department of Oncology and Radiotherapy, University Hospital of Split, Croatia, from October 2015 until March 2020. The outcomes analyzed were the occurrence of castration-resistant disease (CRPC) and death from any cause (OS). The median follow-up was 54 (50-73) months. Forty-six (63%) patients developed CRPC and 34 (47%) died during the follow-up. The median time to CRPC and median OS were 16.2 and 58.4 months, respectively. The risk of CRPC was higher for patients with high (above median) values of serum alkaline phosphatase (ALP) (HR=2.4; 95% CI [1.4-4.5]), lactate dehydrogenase (LDH) (HR=1.98; 95% CI [1.1-3.7]), prostate-specific antigen (PSA) (HR=1.8; 95% CI [1.1-3]), ECOG performance status >1 (HR=2; 95% CI [1.2-3.3]) and HV disease (HR=1.9; 95% CI [1.1-3.1]). The risk of any-cause death was higher in patients with high values of ALP, LDH, and ECOG performance status >1. The predictive value of LDH was independent of disease volume. A set of baseline characteristics could be used in conjunction with disease volume in deciding on the optimal treatment strategy for patients with de novo mHSPC.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"476-484"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9885600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TRIM31 promotes the progression of oral squamous cell carcinoma through upregulating AKT phosphorylation and subsequent cellular glycolysis. TRIM31通过上调AKT磷酸化和随后的细胞糖酵解促进口腔鳞状细胞癌的进展。
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230319N155
Sheng-Qi Sang, Yi-Jie Zhao, Meng Wang, Xiao-Qi Zhong, Zhi-Cheng Yang, Meng-Meng Lu

The regulation of protein kinase B (AKT) phosphorylation by Tripartite motif-containing protein 31 (TRIM31) is implicated as an essential mechanism in the progression of many malignant tumors. Nevertheless, the function of the TRIM31/AKT pathway in oral squamous cell carcinoma (OSCC) remains elusive. Here, immunohistochemistry analysis of human OSCC tissue microarrays indicated significantly higher levels of TRIM31 and phosphorylated AKT (p-AKT) in OSCC tumors than in adjacent tissue samples. Also, we detected a positive association between TRIM31 expression and clinical OSCC development. In in vitro studies, TRIM31 knockdown severely impaired OSCC cell growth, invasion, and migration. By contrast, TRIM31 overexpression improved these cell behaviors, while subsequent AKT inhibition abrogated the effect. In vivo tumorigenesis experiments using nude mice also validated the effects of TRIM31/AKT signaling in tumor growth. Furthermore, TRIM31 upregulation facilitated glucose uptake, as well as lactate and adenosine triphosphate production of OSCC cells, while such positive effects on glycolysis and malignant cell phenotypes were reversed by treatment with AKT or glycolysis inhibitors. In conclusion, TRIM31 may improve OSCC progression by enhancing AKT phosphorylation and subsequent glycolysis. Hence, TRIM31 has the potential as a treatment target in OSCC.

含有Tripartite motif-containing protein 31 (TRIM31)对蛋白激酶B (AKT)磷酸化的调控被认为是许多恶性肿瘤发展的重要机制。然而,TRIM31/AKT通路在口腔鳞状细胞癌(OSCC)中的功能尚不清楚。在此,对人OSCC组织微阵列的免疫组化分析显示,OSCC肿瘤中TRIM31和磷酸化AKT (p-AKT)的水平明显高于邻近组织样本。此外,我们还发现TRIM31的表达与临床OSCC的发展呈正相关。在体外研究中,TRIM31敲低严重损害了OSCC细胞的生长、侵袭和迁移。相比之下,TRIM31过表达改善了这些细胞行为,而随后的AKT抑制则消除了这种作用。裸鼠体内肿瘤发生实验也验证了TRIM31/AKT信号在肿瘤生长中的作用。此外,TRIM31上调促进了OSCC细胞的葡萄糖摄取以及乳酸和三磷酸腺苷的产生,而AKT或糖酵解抑制剂对糖酵解和恶性细胞表型的积极作用被逆转。综上所述,TRIM31可能通过增强AKT磷酸化和随后的糖酵解来改善OSCC的进展。因此,TRIM31有潜力作为OSCC的治疗靶点。
{"title":"TRIM31 promotes the progression of oral squamous cell carcinoma through upregulating AKT phosphorylation and subsequent cellular glycolysis.","authors":"Sheng-Qi Sang,&nbsp;Yi-Jie Zhao,&nbsp;Meng Wang,&nbsp;Xiao-Qi Zhong,&nbsp;Zhi-Cheng Yang,&nbsp;Meng-Meng Lu","doi":"10.4149/neo_2023_230319N155","DOIUrl":"https://doi.org/10.4149/neo_2023_230319N155","url":null,"abstract":"<p><p>The regulation of protein kinase B (AKT) phosphorylation by Tripartite motif-containing protein 31 (TRIM31) is implicated as an essential mechanism in the progression of many malignant tumors. Nevertheless, the function of the TRIM31/AKT pathway in oral squamous cell carcinoma (OSCC) remains elusive. Here, immunohistochemistry analysis of human OSCC tissue microarrays indicated significantly higher levels of TRIM31 and phosphorylated AKT (p-AKT) in OSCC tumors than in adjacent tissue samples. Also, we detected a positive association between TRIM31 expression and clinical OSCC development. In in vitro studies, TRIM31 knockdown severely impaired OSCC cell growth, invasion, and migration. By contrast, TRIM31 overexpression improved these cell behaviors, while subsequent AKT inhibition abrogated the effect. In vivo tumorigenesis experiments using nude mice also validated the effects of TRIM31/AKT signaling in tumor growth. Furthermore, TRIM31 upregulation facilitated glucose uptake, as well as lactate and adenosine triphosphate production of OSCC cells, while such positive effects on glycolysis and malignant cell phenotypes were reversed by treatment with AKT or glycolysis inhibitors. In conclusion, TRIM31 may improve OSCC progression by enhancing AKT phosphorylation and subsequent glycolysis. Hence, TRIM31 has the potential as a treatment target in OSCC.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"402-415"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9927207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression. nop2介导的XPD m5C甲基化与肝细胞癌进展相关。
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230110N17
Guo-Fang Sun, Hao Ding

Hepatocellular carcinoma (HCC) is a common malignant tumor with high mortality. Our previous study has confirmed that XPD acts as an anti-oncogene and is downregulated in HCC. The mechanism of XPD downregulation in HCC is unclear. In this work, we obtained the datasets related to HCC patients from GSE76427, LIRI-JP, and TCGA-LIHC cohorts. Among 15 m5C regulators (NSUN2, NSUN3, NSUN4, NSUN5, NSUN6, NSUN7, DNMT1, TRDMT1, DNMT3A, DNMT3B and NOP2, TET1, TET2, and TET3, ALYREF), 14 m5C regulators were upregulated in tumor tissues of HCC patients, except for TET2. HCC patients were divided into Cluster A and B with different m5C methylation patterns. Cluster B was enriched in metabolism-related signaling pathways, and Cluster A was prominently associated with the cell cycle signaling pathway. Moreover, XPD was positively correlated with NOP2. Cluster B exhibited upregulation of XPD and had an obvious survival advantage with respect to Cluster A. Additionally, NOP2 and XPD were downregulated in HCC tumors and cells. In vitro assays revealed that NOP2 overexpression enhanced XPD expression by elevating the m5C methylation of XPD, which contributed to inhibit proliferation, migration, and invasion of HCC cells. In conclusion, this work demonstrated that XPD mRNA stability was elevated by NOP2-mediated m5C methylation modification and then inhibited the malignant progression of HCC, suggesting that XPD may be a potential target for HCC treatment.

肝细胞癌(HCC)是一种常见的恶性肿瘤,死亡率高。我们前期的研究已经证实XPD作为一种抗癌基因在HCC中下调。XPD在HCC中的下调机制尚不清楚。在这项工作中,我们从GSE76427、li - jp和TCGA-LIHC队列中获得了与HCC患者相关的数据集。在15个m5C调节因子(NSUN2、NSUN3、NSUN4、NSUN5、NSUN6、NSUN7、DNMT1、TRDMT1、DNMT3A、DNMT3B和NOP2、TET1、TET2、TET3、ALYREF)中,除TET2外,HCC患者肿瘤组织中有14个m5C调节因子上调。HCC患者分为A类和B类,m5C甲基化模式不同。簇B富含代谢相关信号通路,而簇A与细胞周期信号通路显著相关。XPD与NOP2呈正相关。簇B表现出XPD的上调,相对于簇a具有明显的生存优势。此外,NOP2和XPD在HCC肿瘤和细胞中下调。体外实验显示,NOP2过表达通过提高XPD的m5C甲基化来增强XPD的表达,从而抑制HCC细胞的增殖、迁移和侵袭。综上所述,本研究表明,通过nop2介导的m5C甲基化修饰,XPD mRNA的稳定性升高,进而抑制HCC的恶性进展,提示XPD可能是HCC治疗的潜在靶点。
{"title":"NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression.","authors":"Guo-Fang Sun,&nbsp;Hao Ding","doi":"10.4149/neo_2023_230110N17","DOIUrl":"https://doi.org/10.4149/neo_2023_230110N17","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a common malignant tumor with high mortality. Our previous study has confirmed that XPD acts as an anti-oncogene and is downregulated in HCC. The mechanism of XPD downregulation in HCC is unclear. In this work, we obtained the datasets related to HCC patients from GSE76427, LIRI-JP, and TCGA-LIHC cohorts. Among 15 m5C regulators (NSUN2, NSUN3, NSUN4, NSUN5, NSUN6, NSUN7, DNMT1, TRDMT1, DNMT3A, DNMT3B and NOP2, TET1, TET2, and TET3, ALYREF), 14 m5C regulators were upregulated in tumor tissues of HCC patients, except for TET2. HCC patients were divided into Cluster A and B with different m5C methylation patterns. Cluster B was enriched in metabolism-related signaling pathways, and Cluster A was prominently associated with the cell cycle signaling pathway. Moreover, XPD was positively correlated with NOP2. Cluster B exhibited upregulation of XPD and had an obvious survival advantage with respect to Cluster A. Additionally, NOP2 and XPD were downregulated in HCC tumors and cells. In vitro assays revealed that NOP2 overexpression enhanced XPD expression by elevating the m5C methylation of XPD, which contributed to inhibit proliferation, migration, and invasion of HCC cells. In conclusion, this work demonstrated that XPD mRNA stability was elevated by NOP2-mediated m5C methylation modification and then inhibited the malignant progression of HCC, suggesting that XPD may be a potential target for HCC treatment.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"340-349"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9927206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
What is the best time for postoperative radiation therapy in pN1 prostate cancer? pN1前列腺癌术后放射治疗的最佳时机是什么?
IF 3 4区 医学 Q3 ONCOLOGY Pub Date : 2023-06-01 DOI: 10.4149/neo_2023_230403N182
Francesco Alessandro Mistretta, Stefano Luzzago, Giulia Marvaso, Giulia Corrao, Ilaria Sabatini, Matteo Fontana, Federico Mastroleo, Mattia Zaffaroni, Maria Giulia Vincini, Ettore Di Trapani, Gabriele Cozzi, Roberto Bianchi, Matteo Ferro, Ottavio de Cobelli, Barbara Alicja Jereczek-Fossa, Gennaro Musi

We retrospectively compared long-term biochemical recurrence rates (BCR) in pN1 PCa patients that underwent adjuvant radiotherapy (aRT) vs. no aRT/early salvage (esRT) after robot-assisted radical prostatectomy and extended pelvic lymphadenectomy. All PCa pN1 M0 patients treated at a single high-volume center between 2010 and 2020 were analyzed. Patients with <10 LNs yield, or >10 positive LNs, or persistently detectable PSA after RARP were excluded. Kaplan-Meier (KM) plots depicted BCR rates. Multivariable Cox regression models (MCRMs) focused on predictors of BCR. The cumulative incidence plot depicted BCR rates after propensity score (PS) matching (ratio 1:1). 220 pN1 patients were enrolled, 133 (60.4%) treated with aRT and 87 (39.6%) with no-aRT/esRT. aRT patients were older, with higher rates of postoperative ISUP grade group 4-5, and higher rates of pT3b stage. The actuarial BCR was similar (aRT 39.8% vs. no-aRT/esRT 40.2%; p=1). Median time to BCR was 62 vs. 38 months in aRT vs. no-aRT/esRT patients (p=0.001). In MCRMs, patients managed with no-aRT/esRT were associated with higher rates of BCR over time (hazard ratio [HR]: 3.27, p<0.001). ISUP grade group 5 (HR: 2.18, p<0.01) was an independent predictor of BCR. In PS-matched cumulative incidence plots, the BCR rate was significantly higher in the aRT group (76.4 vs. 40.4%; p<0.01). Patients managed with no-aRT/esRT experienced BCR approximately two years before the aRT group. Despite, the important BCR benefit after aRT, this treatment strategy is underused in daily practice.

我们回顾性比较了机器人辅助根治性前列腺切除术和盆腔淋巴结切除术后,接受辅助放疗(aRT)与未接受aRT/早期挽救(esRT)的pN1型前列腺癌患者的长期生化复发率(BCR)。分析2010年至2020年间在单一大容量中心治疗的所有PCa pN1 M0患者。排除了10例LNs阳性或RARP后PSA持续检测的患者。Kaplan-Meier (KM)图描述了BCR率。多变量Cox回归模型(MCRMs)侧重于BCR的预测因子。累积发生率图描述了倾向评分(PS)匹配后的BCR发生率(比例为1:1)。纳入220例pN1患者,133例(60.4%)接受aRT治疗,87例(39.6%)接受无aRT/esRT治疗。aRT患者年龄较大,术后ISUP分级4-5组发生率较高,pT3b期发生率较高。精算BCR相似(aRT 39.8% vs. no-aRT/esRT 40.2%;p = 1)。aRT和no-aRT/esRT患者达到BCR的中位时间分别为62个月和38个月(p=0.001)。在MCRMs中,无art /esRT治疗的患者随着时间的推移BCR率更高(风险比[HR]: 3.27, p
{"title":"What is the best time for postoperative radiation therapy in pN1 prostate cancer?","authors":"Francesco Alessandro Mistretta,&nbsp;Stefano Luzzago,&nbsp;Giulia Marvaso,&nbsp;Giulia Corrao,&nbsp;Ilaria Sabatini,&nbsp;Matteo Fontana,&nbsp;Federico Mastroleo,&nbsp;Mattia Zaffaroni,&nbsp;Maria Giulia Vincini,&nbsp;Ettore Di Trapani,&nbsp;Gabriele Cozzi,&nbsp;Roberto Bianchi,&nbsp;Matteo Ferro,&nbsp;Ottavio de Cobelli,&nbsp;Barbara Alicja Jereczek-Fossa,&nbsp;Gennaro Musi","doi":"10.4149/neo_2023_230403N182","DOIUrl":"https://doi.org/10.4149/neo_2023_230403N182","url":null,"abstract":"<p><p>We retrospectively compared long-term biochemical recurrence rates (BCR) in pN1 PCa patients that underwent adjuvant radiotherapy (aRT) vs. no aRT/early salvage (esRT) after robot-assisted radical prostatectomy and extended pelvic lymphadenectomy. All PCa pN1 M0 patients treated at a single high-volume center between 2010 and 2020 were analyzed. Patients with <10 LNs yield, or >10 positive LNs, or persistently detectable PSA after RARP were excluded. Kaplan-Meier (KM) plots depicted BCR rates. Multivariable Cox regression models (MCRMs) focused on predictors of BCR. The cumulative incidence plot depicted BCR rates after propensity score (PS) matching (ratio 1:1). 220 pN1 patients were enrolled, 133 (60.4%) treated with aRT and 87 (39.6%) with no-aRT/esRT. aRT patients were older, with higher rates of postoperative ISUP grade group 4-5, and higher rates of pT3b stage. The actuarial BCR was similar (aRT 39.8% vs. no-aRT/esRT 40.2%; p=1). Median time to BCR was 62 vs. 38 months in aRT vs. no-aRT/esRT patients (p=0.001). In MCRMs, patients managed with no-aRT/esRT were associated with higher rates of BCR over time (hazard ratio [HR]: 3.27, p<0.001). ISUP grade group 5 (HR: 2.18, p<0.01) was an independent predictor of BCR. In PS-matched cumulative incidence plots, the BCR rate was significantly higher in the aRT group (76.4 vs. 40.4%; p<0.01). Patients managed with no-aRT/esRT experienced BCR approximately two years before the aRT group. Despite, the important BCR benefit after aRT, this treatment strategy is underused in daily practice.</p>","PeriodicalId":19266,"journal":{"name":"Neoplasma","volume":"70 3","pages":"458-467"},"PeriodicalIF":3.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9880267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neoplasma
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1